Mitsubishi UFJ Kokusai Asset Management Co. Ltd. cut its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 10.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,306 shares of the biopharmaceutical company’s stock after selling 3,731 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Alexion Pharmaceuticals were worth $3,931,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Guardian Life Insurance Co. of America increased its stake in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the first quarter valued at $111,000. Independent Portfolio Consultants Inc. increased its stake in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 340 shares in the last quarter. Huntington National Bank increased its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares in the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in shares of Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 100 shares in the last quarter. 95.14% of the stock is currently owned by institutional investors and hedge funds.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 132.93 on Friday. The stock has a 50 day moving average of $129.36 and a 200-day moving average of $122.92. The company has a market capitalization of $29.67 billion, a PE ratio of 57.65 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.42.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912 million during the quarter, compared to the consensus estimate of $846.15 million. During the same period in the previous year, the company posted $1.13 earnings per share. The business’s revenue for the quarter was up 21.1% on a year-over-year basis. Analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Position Lowered by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/12/alexion-pharmaceuticals-inc-alxn-position-lowered-by-mitsubishi-ufj-kokusai-asset-management-co-ltd.html.

ALXN has been the topic of several recent analyst reports. TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, July 14th. Stifel Nicolaus reissued a “buy” rating and issued a $157.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Deutsche Bank AG reduced their target price on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $156.89.

In other news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at $869,828.10. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Ludwig Hantson acquired 10,000 shares of the stock in a transaction dated Wednesday, June 14th. The shares were bought at an average cost of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the transaction, the chief executive officer now owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 2,019,734 shares of company stock valued at $235,606,846. Corporate insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.